Detalhe da pesquisa
1.
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
Lancet Oncol;
18(4): 464-472, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28268064
2.
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
J Transl Med;
14: 95, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27095081
3.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
J Transl Med;
14(1): 232, 2016 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27484791
4.
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
J Transl Med;
13: 9, 2015 Jan 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25592374
5.
Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports.
Melanoma Res;
32(3): 200-204, 2022 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35377860
6.
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Melanoma Res;
28(1): 65-70, 2018 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29227333
7.
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
J Clin Endocrinol Metab;
101(11): 4431-4439, 2016 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27571185
8.
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
Melanoma Res;
26(2): 157-63, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26636909
9.
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Melanoma Res;
25(6): 550-4, 2015 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26512791
10.
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
Melanoma Res;
25(1): 68-74, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25396684
11.
Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Melanoma Res;
25(2): 180-3, 2015 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25643238
12.
Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Melanoma Res;
25(4): 357-61, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26050145